Medical Condition News

RSS

Vanderbilt Heart and Vascular Institute offers new blood test to predict heart disease

Just in time for American Heart Month, Vanderbilt Heart and Vascular Institute is offering a new blood test that can predict if a patient is at high risk for heart disease. Vanderbilt is among the first institutions in the country, and the only one in Tennessee, to offer this test.

5 Feb 2010

Aradigm's first U.S. sale of SUMAVEL DosePro needle-free delivery system triggers $4M milestone payment

Aradigm Corporation announced today that it received the $4 million milestone payment from Zogenix, Inc. (“Zogenix”) based upon the first commercial sale in the U.S. of SUMAVEL* DosePro* (sumatriptan injection) needle-free delivery system. The Company will receive quarterly royalty payments on all SUMAVEL DosePro sales. In 2006, the Company sold all assets related to the Intraject* needle-free injector technology (now rebranded as DosePro) to Zogenix in exchange for milestone and royalty payments.

5 Feb 2010

San Antonio Methodist Hospital upgrades to Leksell Gamma Knife Perfexion system

AMERICAN SHARED HOSPITAL SERVICES, a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services, announced today that it has entered into a contract to supply a Leksell Gamma Knife® PerfexionTM system to Methodist Hospital in San Antonio, Texas. This new Perfexion system, the eighth placed by AMS to date, will replace an existing Gamma Knife supplied by AMS and is expected to begin treating patients later this year.

5 Feb 2010

BioMarin announces update on BMN 110 Phase I/II trial for Morquio A Syndrome

BioMarin Pharmaceutical Inc. today announced an update on the Phase I/II trial for BMN 110 or N-acetylgalactosamine 6-sulfatase (GALNS), intended for the treatment of the lysosomal storage disorder Mucopolysaccharidosis Type IVA (MPS IVA), or Morquio A Syndrome. Preliminary clinical data from the first 24 weeks of the study (12 weeks at 0.1mg/kg and 12 weeks at 1.0 mg/kg) have been evaluated, and BioMarin plans to announce top-line results for the full 36-week study after completion of dosing at 2.0 mg/kg in the second quarter of 2010.

5 Feb 2010

LDDI releases biomonitoring report on environmental neurotoxins in health affected community

The Learning and Developmental Disabilities Initiative (LDDI) today released the first-ever biomonitoring report identifying toxic chemical pollution in people from the learning and developmental disability community.

5 Feb 2010

$AAOS issues new clinical practice guidelines for treating distal radius fractures$

AAOS issues new clinical practice guidelines for treating distal radius fractures

The American Academy of Orthopaedic Surgeons (AAOS) recently approved and released an evidence-based clinical practice guideline on the Treatment of Distal Radius Fractures.

5 Feb 2010

Bioheart initiates REGEN Phase I Clinical Trial for testing genetically modified MyoCell in CHF patients

Bioheart, Inc., announced today that the company has commenced work on its REGEN trial, a Phase I Clinical Trial to test genetically modified MyoCell® in patients suffering from Congestive Heart Failure (CHF). Bioheart’s MyoCell® is a regenerative cell therapy that uses myoblasts, or muscle stem cells,that are grown from a patient’s own muscle. MyoCell® has been tested successfully on patients in four clinical trials.

5 Feb 2010

Use of laparoscopic hepatectomy in treating HCC patients achieves complete resection

Conventional hepatectomy is an effective way to treat hepatocellular carcinoma (HCC). However, it is invasive and stressful. Laparoscopic surgery, a kind of minimally invasive surgery, has recently gained considerable advances.

5 Feb 2010

WORLD Symposium: Protalix Biotherapeutics to present data on taliglucerase alfa Phase III Gaucher disease trial

Protalix Biotherapeutics, Inc. today announced that data from its pivotal Phase III trial of taliglucerase alfa in patients with Gaucher disease will be presented at the Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2010, February 10-12, 2010 in Miami, Florida.

5 Feb 2010

Scientists discover new technique to destroy individual diseased cells

Using lasers and nanoparticles, scientists at Rice University have discovered a new technique for singling out individual diseased cells and destroying them with tiny explosions.

5 Feb 2010

St. Jude Medical receives European approval for Fortify ST ICD and Unify CRT-D defibrillators

St. Jude Medical, Inc. today announced European CE Mark approval and first implants of its Fortify™ and Fortify ST implantable cardioverter defibrillators (ICD) and Unify™ cardiac resynchronization therapy defibrillator (CRT-D). The devices will be fully launched in Europe later this spring, and U.S. versions of the Fortify ICD and Unify CRT-D are expected to be launched later this year. The reduced size of these new devices compared to those of previous generations creates the smallest available device footprint in the industry.

5 Feb 2010

Pfizer, DxS sign agreement to develop a diagnostic test kit for CDX-110 to treat patients with GBM

Pfizer Inc. and DxS (a wholly owned subsidiary of QIAGEN N.V.) today announced that they have entered into an agreement to develop a companion diagnostic test kit for PF-04948568 (CDX-110), an immunotherapy vaccine in development for the treatment of glioblastoma multiforme (GBM).

5 Feb 2010

Paloma Pharmaceuticals receives FDA approval to enter Phase I studies with P529

Paloma Pharmaceuticals, Inc. announced today that it has received acceptance of its IND to enter Phase I studies with Palomid 529 (P529) in patients with age-related macular degeneration (AMD).

5 Feb 2010

Polymedco's automated immunoassay fecal occult blood test system receives FDA clearance

Polymedco, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance of the OC-Sensor Diana, a high throughput automated system for the immunoassay fecal occult blood test (FIT) used for detecting gastrointestinal bleeding associated with disorders such as colorectal cancer, polyps and colitis.

5 Feb 2010

Lux Biosciences seeks US and European marketing approval for LUVENIQ

Lux Biosciences, Inc. today announced its submission of simultaneous regulatory filings to both the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) seeking marketing approval for its investigational drug LUVENIQ™ (LX211; oral voclosporin) for the treatment of noninfectious uveitis involving the intermediate or posterior segments of the eye.

5 Feb 2010

Progenics Pharmaceuticals to present preclinical data of multiplex PI3K inhibitors

Progenics Pharmaceuticals, Inc. today announced the presentation of preclinical data on a series of novel compounds that simultaneously blocked two critical pathways involved in the growth and survival of cancer cells.

4 Feb 2010

Michael J. Fox Foundation announces more than $2.8M in awards to discover biomarkers of PD

The Michael J. Fox Foundation for Parkinson's Research today announced more than $2.8 million in awards for 13 new projects to speed the discovery of biomarkers of PD.

4 Feb 2010

ASTRO and ACR release practice guidelines for new radiation treatments

The American Society for Radiation Oncology (ASTRO) and the American College of Radiology (ACR) have released practice guidelines for image guided radiation therapy (IGRT) and stereotactic body radiation therapy (SBRT) in the February issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of ASTRO.

4 Feb 2010

Global cancer rates could be reduced by 40% with prevention strategies, report says

"Forty percent of the 12 million people diagnosed with cancer worldwide each year could avert the killer disease by protecting themselves against infections and changing their lifestyles, experts said on Tuesday," Reuters reports.

4 Feb 2010

Arizona Oncology physicians provide advanced cancer care for MHC patients

Cancer patients in Marana now have more options for cancer care. Arizona Oncology physicians will now treat patients at Marana Healthcare Clinic (MHC). Drs. Laurie Chen and Y. Haroon Ahmad, medical oncologists, are now actively caring for patients at MHC.

4 Feb 2010

Medical Condition News

Vanderbilt Heart and Vascular Institute offers new blood test to predict heart disease

Aradigm's first U.S. sale of SUMAVEL DosePro needle-free delivery system triggers $4M milestone payment

San Antonio Methodist Hospital upgrades to Leksell Gamma Knife Perfexion system

BioMarin announces update on BMN 110 Phase I/II trial for Morquio A Syndrome

LDDI releases biomonitoring report on environmental neurotoxins in health affected community

AAOS issues new clinical practice guidelines for treating distal radius fractures

Bioheart initiates REGEN Phase I Clinical Trial for testing genetically modified MyoCell in CHF patients

Use of laparoscopic hepatectomy in treating HCC patients achieves complete resection

WORLD Symposium: Protalix Biotherapeutics to present data on taliglucerase alfa Phase III Gaucher disease trial

Scientists discover new technique to destroy individual diseased cells

St. Jude Medical receives European approval for Fortify ST ICD and Unify CRT-D defibrillators

Pfizer, DxS sign agreement to develop a diagnostic test kit for CDX-110 to treat patients with GBM

Paloma Pharmaceuticals receives FDA approval to enter Phase I studies with P529

Polymedco's automated immunoassay fecal occult blood test system receives FDA clearance

Lux Biosciences seeks US and European marketing approval for LUVENIQ

Progenics Pharmaceuticals to present preclinical data of multiplex PI3K inhibitors

Michael J. Fox Foundation announces more than $2.8M in awards to discover biomarkers of PD

ASTRO and ACR release practice guidelines for new radiation treatments

Global cancer rates could be reduced by 40% with prevention strategies, report says

Arizona Oncology physicians provide advanced cancer care for MHC patients

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Latest News